Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease.
與使用鈉-葡萄糖共轉運蛋白-2抑制劑相比，使用胰高血糖素樣肽-1受體激動劑和噻唑烷二酮在代謝功能障礙相關脂肪肝疾病患者中肝臟事件的風險。
Gut 2024-09-06
Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists.
接受鈉葡萄糖共同運輸蛋白2抑制劑或葡萄糖樣肽-1受體激動劑治療的2型糖尿病患者中，肝硬化程度升高的盛行率較低。
Ann Hepatol 2023-08-03
Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status.
2型糖尿病患者在不同NAFLD狀態下接受SGLT-2i和GLP-1RA治療的結果。
JAMA Netw Open 2023-12-31
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease.
第二型糖尿病患者合併輕至中度慢性腎臟疾病時，鈉葡萄糖共同轉運蛋白2抑制劑與葡萄糖樣肽-1受體激動劑的比較效果。
Diabetes Obes Metab 2024-03-14
Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes.
葡萄糖樣肽-1 受體激動劑對代謝異常相關脂肪肝硬化和2型糖尿病患者不良肝臟結果風險的影響。
Aliment Pharmacol Ther 2024-04-10
Prolonged impacts of sodium glucose cotransporter-2 inhibitors on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a retrospective analysis through magnetic resonance imaging.
鈉葡萄糖共同轉運蛋白-2抑制劑對第2型糖尿病代謝異常相關脂肪肝疾病的長期影響：透過磁共振成像的回顧性分析。
Endocr J 2024-05-29
Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.
鈉-葡萄糖共轉運蛋白-2抑制劑與二甲雙胍在2型糖尿病及代謝功能障礙相關脂肪肝疾病患者中對肝臟及非肝臟併發症的協同作用。
Gut 2024-08-09
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
SGLT2 抑制劑與 GLP-1 受體激動劑在 2 型糖尿病中的腎臟與心血管效果比較。
J Am Coll Cardiol 2024-08-14
Retrospective Longitudinal Observational Study on the Long-Term Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetic Japanese Patients.
對於日本2型糖尿病患者，鈉-葡萄糖共轉運蛋白-2抑制劑對代謝功能障礙相關脂肪肝疾病發展的長期影響之回顧性縱向觀察研究。
J Clin Med 2024-08-29
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
GLP-1 受體激動劑與代謝功能障礙相關脂肪肝疾病患者肝硬化及相關併發症的風險。
JAMA Intern Med 2024-09-16
Comparison of kidney and hepatic outcomes among sodium-glucose cotransporter-2 inhibitors: a retrospective study using multiple propensity scores.
鈉-葡萄糖共轉運蛋白-2 抑制劑在腎臟和肝臟結果的比較：使用多重傾向評分的回顧性研究。
J Pharm Health Care Sci 2024-09-16